Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CCEL 
CryoCell International Inc (CCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: CCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.98% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.66M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta 0.65 | 52 Weeks Range 3.57 - 8.27 | Updated Date 12/8/2025 |
52 Weeks Range 3.57 - 8.27 | Updated Date 12/8/2025 | ||
Dividends yield (FY) 16.29% | Basic EPS (TTM) -0.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.49% | Operating Margin (TTM) 24.29% |
Management Effectiveness
Return on Assets (TTM) 4.29% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 41516364 | Price to Sales(TTM) 1.03 |
Enterprise Value 41516364 | Price to Sales(TTM) 1.03 | ||
Enterprise Value to Revenue 1.31 | Enterprise Value to EBITDA 8.05 | Shares Outstanding 8055150 | Shares Floating 4203580 |
Shares Outstanding 8055150 | Shares Floating 4203580 | ||
Percent Insiders 41.98 | Percent Institutions 12.27 |
Upturn AI SWOT
CryoCell International Inc
Company Overview
History and Background
CryoCell International Inc., established in 1989, is a pioneer in the field of stem cell preservation. The company's primary focus has been on collecting, processing, and cryogenically storing umbilical cord blood and tissue stem cells for potential future medical use. Over the years, CryoCell has evolved to offer a broader range of genetic preservation services and has navigated changes in the biotechnology and healthcare landscape.
Core Business Areas
- Stem Cell Preservation: CryoCell International's core business involves collecting, processing, and cryogenically preserving stem cells derived from umbilical cord blood and tissue. These cells are stored for potential therapeutic use in treating various diseases and conditions. The company offers different preservation plans to families.
- Genetic Preservation Services: Beyond stem cells, CryoCell has expanded into offering genetic preservation services, allowing individuals to store DNA samples for potential future research or diagnostic purposes.
Leadership and Structure
CryoCell International Inc. operates with a management team responsible for overseeing its operations, research and development, sales, and customer service. The specific details of the current leadership team and detailed organizational structure are typically found in the company's annual reports and proxy statements.
Top Products and Market Share
Key Offerings
- Cord Blood Stem Cell Preservation: CryoCell offers the cryopreservation of hematopoietic stem cells from umbilical cord blood. This service is aimed at providing a biological insurance policy for families, with potential applications in treating blood disorders, cancers, and certain genetic diseases. Competitors include publicly traded companies and private entities in the cord blood banking industry like Cord Blood Registry (CBR), StemGen, and others. Market share data for individual product lines is not readily available publicly, but the cord blood banking market is fragmented.
- Cord Tissue Stem Cell Preservation: This service focuses on preserving mesenchymal stem cells (MSCs) found in the umbilical cord tissue. MSCs have shown potential in regenerative medicine for various tissue repair and inflammatory conditions. This is a relatively newer area compared to cord blood banking, with similar competitors offering comparable services.
- DNA Preservation: CryoCell provides services for the long-term storage of DNA samples. This offering caters to individuals interested in genetic research, personalized medicine, or familial genealogy. Competitors in this niche include specialized DNA banks and research institutions.
Market Dynamics
Industry Overview
The stem cell preservation industry, particularly cord blood banking, is driven by advancements in regenerative medicine and growing awareness among expectant parents about the potential benefits of stem cell therapies. The market is influenced by regulatory environments, scientific research breakthroughs, and consumer education. The broader biotechnology and healthcare sectors also play a significant role.
Positioning
CryoCell International Inc. has positioned itself as a long-standing player in the stem cell preservation market, emphasizing its experience and established infrastructure. Its competitive advantages lie in its history, established client base, and potential for expanding its service offerings within the biotechnology and genetic preservation sectors. However, the market is competitive, and ongoing innovation is crucial.
Total Addressable Market (TAM)
The Total Addressable Market (TAM) for stem cell preservation is substantial and growing, driven by the increasing incidence of diseases treatable with stem cells and the expanding applications of regenerative medicine. Estimates for the global cord blood banking market alone vary, but figures often range in the billions of dollars annually. CryoCell's positioning within this TAM is dependent on its ability to capture market share through effective marketing, competitive pricing, and demonstrable scientific backing for its services.
Upturn SWOT Analysis
Strengths
- Pioneering experience in stem cell preservation.
- Established brand recognition and customer base.
- Potential for diversification into related genetic services.
- Proprietary processing and storage technologies.
Weaknesses
- Reliance on consumer adoption and marketing effectiveness.
- Evolving scientific understanding and clinical applications of stem cells can impact perceived value.
- Potential for regulatory changes affecting the industry.
- Competition from established and emerging players.
Opportunities
- Advancements in stem cell therapies and regenerative medicine.
- Expansion into international markets.
- Strategic partnerships with healthcare providers and research institutions.
- Development of new genetic testing and preservation services.
Threats
- Emergence of superior or more cost-effective stem cell therapies.
- Negative publicity or adverse outcomes related to stem cell treatments.
- Increased competition and price wars.
- Economic downturns impacting consumer discretionary spending.
Competitors and Market Share
Key Competitors
- National Cord Blood Services (NCBS) - Not publicly traded
- Cord Blood Registry (CBR) - Not publicly traded
- StemGen - Not publicly traded
- Various smaller regional and international players
Competitive Landscape
CryoCell operates in a competitive landscape where differentiation is achieved through trust, scientific credibility, customer service, and pricing. Its advantages lie in its long history and established infrastructure. However, it faces challenges from larger, privately held competitors with significant marketing budgets and from emerging technologies that may offer alternative solutions for stem cell therapies.
Growth Trajectory and Initiatives
Historical Growth: CryoCell's historical growth has been influenced by the increasing awareness and adoption of cord blood banking, as well as its efforts to diversify into related genetic services. Periods of expansion have likely been driven by successful marketing campaigns and the development of new service offerings.
Future Projections: Future projections for CryoCell International Inc. would depend on analyst reports and the company's strategic initiatives. These projections would consider the growth of the regenerative medicine market, competitive landscape, and the company's ability to innovate and expand its service portfolio.
Recent Initiatives: Recent strategic initiatives would likely focus on enhancing customer acquisition, optimizing operational efficiency, exploring new therapeutic applications for stored stem cells, and potentially expanding its genetic preservation offerings.
Summary
CryoCell International Inc. is a veteran in the stem cell preservation market with a history of innovation. Its core strength lies in its established presence and experience in cord blood and tissue banking. However, the company faces significant competition and must continuously adapt to evolving scientific advancements and consumer demand. Future success hinges on its ability to leverage new therapeutic discoveries, expand its service offerings beyond traditional banking, and effectively communicate the value proposition of its services in a dynamic healthcare landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (e.g., SEC filings for historical financial data)
- Industry research reports
- Financial news outlets
- Company press releases
Disclaimers:
This JSON output is an analysis based on publicly available information and general industry knowledge. It is not intended as financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data and financial figures are estimates and may not be precise or current. Specific details on leadership, current financial performance, and up-to-the-minute market share require access to real-time financial data platforms and company disclosures.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com | ||
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.